We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Prescription of Brand-Name Medications When Generic Alternatives Are Available—Patently Unfair

Walid F. Gellad, MD, MPH1,2,3; Chester B. Good, MD, MPH1,2,3,4,5
[+] Author Affiliations
1Division of General Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
2Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania
3Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
4Pharmacy Benefits Management Services, US Department of Veterans Affairs, Hines, Illinois
5Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania
JAMA Intern Med. 2016;176(9):1323-1324. doi:10.1001/jamainternmed.2016.3389.
Text Size: A A A
Published online


In December 1996, 8 days before Christmas, the US Food and Drug Administration (FDA) approved Lipitor (atorvastatin; Pfizer) for the treatment of hyperlipidemia. Lipitor would become one of the most profitable prescription drugs in history, bringing in $130 billion in sales during its lifetime as a brand-name product and peaking at nearly $13 billion in sales in 2006 alone.13 Lipitor was far from the first statin in its class (simvastatin, pravastatin, and fluvastatin were already on the market), but 1996 was also the year that the FDA began allowing direct-to-consumer broadcast advertising. Lipitor was aggressively marketed based on its more potent lowering of cholesterol levels compared with other statins.1

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Number of Monthly Prescriptions for Statins in the Veterans Affairs Healthcare System

Data are from the VA Pharmacy Benefits Management national dispensing records from December 2010 to May 2013. The vertical lines represent the months when generic atorvastatin first entered the market with limited competition (December 2011) and 6 months later on entry of additional generic products and full generic competition (June 2012).

aIncludes combination products with niacin.

bIncludes fluvastatin, pitavastatin, and the combination of ezetimibe and simvastatin.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Confidence Intervals Become Narrower as the Number of Events Increases

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
What are the Results?